Tirzepatide for Weight Loss
The first dual-action GIP/GLP-1 medication, delivering the highest weight loss in clinical trials.
Reviewed by GlobalGLP1 editorial team • Last reviewed March 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Tirzepatide is the active ingredient in Mounjaro (for type 2 diabetes) and Zepbound (for weight loss). It is the first medication that targets two hunger hormones at once: GIP and GLP-1. By activating both, it produces stronger weight loss and blood sugar control than older GLP-1-only medications like semaglutide. In the largest clinical trial, people on the highest dose lost an average of 22.5% of their body weight, more than any other FDA-approved weight loss drug.
How Tirzepatide Works
Tirzepatide works by activating two hormones your body already makes: GIP and GLP-1. Most older weight loss medications only target one. Together, these hormones tell your brain you are full, slow down how fast food leaves your stomach, help the pancreas release insulin after meals, and may improve how your body burns and stores fat. You take it as a once-weekly shot (belly, thigh, or upper arm). The dual-hormone approach is why tirzepatide tends to produce more weight loss than single-target drugs like semaglutide.
FDA Approval
Mounjaro
Type 2 diabetes mellitus
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly injection
Zepbound
Chronic weight management
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly injection
How You Take It
The full dose build-up takes about 5 to 6 months. Many people get excellent results at 10 mg without needing the highest dose. Your doctor will adjust based on your weight loss, blood sugar, and how your stomach handles it.
How Much Weight You Can Lose
In the main weight loss trial, people on tirzepatide 15 mg lost an average of 22.5% of their body weight over 72 weeks (about 17 months). At 10 mg, the average was 21.4%. Over a third of people on the highest dose lost 25% or more. For a 200-pound person, 22.5% is roughly 45 pounds.
Blood sugar effect: 1.9 to 2.6 points (Mounjaro, for diabetes)
Side Effects
Common Side Effects
- Nausea (about 29% of users at the 15 mg dose in SURMOUNT-1; usually worst during dose increases and eases over time)
- Diarrhea (about 23% of users; typically mild and short-lived)
- Decreased appetite (common; this is part of how the drug works)
- Vomiting (about 13% of users; tends to drop off after the first month or two)
- Constipation (about 12% of users)
- Abdominal pain (about 10% of users; usually mild)
- Indigestion / upset stomach (about 9% of users)
- Injection site reactions (uncommon; mild redness near the shot)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, rodent studies)
- Hypoglycemia (with insulin or sulfonylureas)
- Severe GI events
- Allergic reactions including anaphylaxis
Managing side effects: Similar pattern to semaglutide: stomach-related side effects show up most during the first few weeks and around dose increases, then ease as your body adjusts. The slow dose build-up exists for this reason. Eating smaller, more frequent meals and avoiding high-fat foods help. If vomiting is persistent or severe, contact your provider. They can slow or pause the dose escalation.
Tirzepatide Cost & Savings (2026)
Savings programs: Eli Lilly offers the Zepbound Savings Card (commercially insured patients may pay as low as $25/month) and the LillyDirect platform for direct-to-patient delivery.
Who Should Not Take Tirzepatide
- Personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to tirzepatide or any ingredient in the medication
- Pregnancy or planning to become pregnant (stop at least 1 month before conception)
- Severe stomach or intestinal disease
Heart Health
Two major trials studied tirzepatide's effect on the heart. SURPASS-CVOT (published late 2025) confirmed it is as safe for the heart as other diabetes medications, and showed a reduction in the combined risk of heart attack, stroke, and procedures like stenting. Separately, the SUMMIT trial (2024) found that people with obesity and heart failure who took tirzepatide had 38% fewer heart failure events and 56% fewer hospitalizations for heart failure compared to placebo.
What this means for you: Tirzepatide is confirmed safe for the heart. If you have obesity and heart failure, the SUMMIT results are especially relevant because they showed real reductions in hospitalizations, not just weight loss.
What to Expect, Month by Month
Noticeable decrease in hunger and food noise. Some patients report reduced cravings for high-calorie foods specifically.
Consistent weight loss begins during dose escalation. Average 3-5% body weight lost. Dual GIP/GLP-1 action accelerates early results.
Approaching maintenance dose (10-15 mg). Steady 1-2.5 lbs per week loss. Blood sugar improvements prominent.
Average 15-20% body weight lost. Dramatic improvements in metabolic health markers, blood pressure, and lipids.
Weight loss plateau at 20-22.5% average. Some patients achieve 25%+ loss. Maintenance phase with sustained metabolic benefits.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will likely reduce your insulin dose by 20 to 50% when starting tirzepatide, and may also lower your sulfonylurea dose.
Because tirzepatide slows digestion, pills you take by mouth may absorb differently. This is most noticeable during the first few months when dose changes are happening and stomach effects are strongest.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting or changing your tirzepatide dose.
Birth control pills may absorb less effectively during the first weeks of treatment. Consider backup contraception (condoms) during the first 4 weeks and for 4 weeks after each dose increase, or switch to a non-oral method (patch, ring, IUD).
Special Situations
Do not use during pregnancy. Stop tirzepatide at least 1 month before trying to conceive. Animal studies showed harm to the fetus at high doses.
No dose change needed for mild or moderate kidney issues. Limited data in severe kidney disease. Watch for dehydration from nausea and vomiting, which can worsen kidney function.
No dose change needed for mild or moderate liver issues. Not studied in severe liver disease.
No dose change needed. Clinical trials included people aged 65 to 75. Slower dose increases may help reduce stomach side effects in older adults.
Not yet FDA-approved for adolescents. Clinical trials in teens (SURMOUNT-TEENS) are in progress. Some doctors prescribe it off-label for teens with severe obesity.
What Happens If You Stop
In the SURMOUNT-4 trial, people who stopped tirzepatide after 36 weeks regained about two-thirds of the weight they had lost over the following year. People who stayed on it continued to lose weight. This is why most doctors recommend staying on treatment long-term if it is working.
How to make stopping easier: Building healthy eating habits and regular exercise while on the medication is the best insurance against regain. Some doctors are exploring lower maintenance doses to keep weight off at lower cost. Start planning your long-term approach before stopping.
Tirzepatide FAQs
Clinical trials suggest tirzepatide produces greater average weight loss (20-22.5%) compared to semaglutide (15-17%). However, individual responses vary. The SURPASS-2 trial directly compared Mounjaro to Ozempic and showed superior A1C reduction and weight loss with tirzepatide.
Both contain tirzepatide at the same doses. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved for chronic weight management. Your doctor will prescribe the appropriate one based on your diagnosis.
Appetite reduction typically begins within 1-2 weeks. Measurable weight loss usually starts after 4-8 weeks as doses escalate. Full weight loss effects develop over 12-18 months at the maintenance dose.
Yes. Zepbound is FDA-approved for weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related condition, regardless of diabetes status.
Tirzepatide is the only dual GIP/GLP-1 receptor agonist. By targeting both receptors, it provides enhanced metabolic benefits that single-target GLP-1 medications like semaglutide don't offer. This dual mechanism is believed to contribute to its superior efficacy.
Long-term data (3+ years) is still being collected. The SURMOUNT trials showed sustained weight loss over 72 weeks with continued use. Like semaglutide, weight regain is expected after discontinuation. Cardiovascular outcome trials are ongoing.
Find Clinics Offering Tirzepatide
Compare Tirzepatide providers by pricing, telehealth availability, and patient ratings.
Search Tirzepatide Clinics →Related Tirzepatide resources
Find Tirzepatide Clinics by State
Ready to start Tirzepatide?
Search our directory of 2,888 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.